Загрузка...
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
BACKGROUND: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations. OBJECTIV...
Сохранить в:
| Формат: | Статья |
|---|---|
| Язык: | en |
| Опубликовано: |
Dove Medical Press
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3402007/ https://ncbi.nlm.nih.gov/pubmed/22826637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S21979 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|